Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Huntington Ingalls Industries Inc (HII) vs Nuwellis Inc (NUWE) Price & Performance

Huntington Ingalls Industries IncTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Huntington Ingalls Industries Inc vs Nuwellis Inc — how do they compare? Huntington Ingalls Industries Inc trades at $269.95 (market cap $10.64B), while Nuwellis Inc trades at $2.9 (market cap $1.09M). The key difference: Huntington Ingalls Industries Inc is far larger — about 9761.5× Nuwellis Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.04% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.

HIINUWE
Market Cap
$10.64B$1.09M
Sector
TechnologyTechnology
52-Week High
$453.73$527.46
52-Week Low
$252.93$2.80
Enterprise Value
$13.36B-$722.58K
Dividend Yield
2.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Huntington Ingalls Industries Inc

HII trades at $270.04, up 0.34% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company shows solid fundamentals with a P/E of 17.49 and ROE of 12.2%, supported by three consecutive quarterly earnings beats. Recent news highlights contract wins and shipbuilding milestones, reinforcing its defense sector presence. Cash flow improved to a net positive $49 million in 2026 from a net outflow of $57 million in 2025.

The outlook is cautiously optimistic given analyst consensus targets near $354.50, though technical resistance at $273 poses a near-term hurdle. Risks include execution delays on defense contracts and macroeconomic pressures on government spending. The stock offers value with a below-sector P/S of 0.82, but investors should monitor Q2 2026 earnings due July 30 for margin sustainability.

Nuwellis Inc

NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.

Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE